257 related articles for article (PubMed ID: 33162940)
1. The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar.
Brent MB; Thomsen JS; Brüel A
Front Endocrinol (Lausanne); 2020; 11():588773. PubMed ID: 33162940
[TBL] [Abstract][Full Text] [Related]
2. Teriparatide and Abaloparatide Have a Similar Effect on Bone in Mice.
Brent MB; Stoltenborg FE; Brüel A; Thomsen JS
Front Endocrinol (Lausanne); 2021; 12():628994. PubMed ID: 33953694
[TBL] [Abstract][Full Text] [Related]
3. PTH (1-34) and growth hormone in prevention of disuse osteopenia and sarcopenia in rats.
Brent MB; Brüel A; Thomsen JS
Bone; 2018 May; 110():244-253. PubMed ID: 29475111
[TBL] [Abstract][Full Text] [Related]
4. Additive effect of PTH (1-34) and zoledronate in the prevention of disuse osteopenia in rats.
Vegger JB; Nielsen ES; Brüel A; Thomsen JS
Bone; 2014 Sep; 66():287-95. PubMed ID: 24970039
[TBL] [Abstract][Full Text] [Related]
5. Anti-sclerostin antibodies and abaloparatide have additive effects when used as a countermeasure against disuse osteopenia in female rats.
Brent MB; Brüel A; Thomsen JS
Bone; 2022 Jul; 160():116417. PubMed ID: 35398589
[TBL] [Abstract][Full Text] [Related]
6. PTH (1-34), but not strontium ranelate counteract loss of trabecular thickness and bone strength in disuse osteopenic rats.
Brüel A; Vegger JB; Raffalt AC; Andersen JE; Thomsen JS
Bone; 2013 Mar; 53(1):51-8. PubMed ID: 23246791
[TBL] [Abstract][Full Text] [Related]
7. Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats.
Bahar H; Gallacher K; Downall J; Nelson CA; Shomali M; Hattersley G
Calcif Tissue Int; 2016 Nov; 99(5):489-499. PubMed ID: 27395059
[TBL] [Abstract][Full Text] [Related]
8. Disuse-induced loss of bone mineral density and bone strength is attenuated by post-lactational bone gain in NMRI mice.
Sørensen TG; Brent MB; Thomsen JS; Brüel A
Bone; 2020 Feb; 131():115183. PubMed ID: 31794846
[TBL] [Abstract][Full Text] [Related]
9. Short-term glucocorticoid excess blunts abaloparatide-induced increase in femoral bone mass and strength in mice.
Brent MB; Thomsen JS; Brüel A
Sci Rep; 2021 Jun; 11(1):12258. PubMed ID: 34112892
[TBL] [Abstract][Full Text] [Related]
10. Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia.
Chandler H; Brooks DJ; Hattersley G; Bouxsein ML; Lanske B
Osteoporos Int; 2019 Aug; 30(8):1607-1616. PubMed ID: 31053927
[TBL] [Abstract][Full Text] [Related]
11. A novel flavonoid C-glucoside from Ulmus wallichiana preserves bone mineral density, microarchitecture and biomechanical properties in the presence of glucocorticoid by promoting osteoblast survival: a comparative study with human parathyroid hormone.
Khan MP; Mishra JS; Sharan K; Yadav M; Singh AK; Srivastava A; Kumar S; Bhaduaria S; Maurya R; Sanyal S; Chattopadhyay N
Phytomedicine; 2013 Nov; 20(14):1256-66. PubMed ID: 23928508
[TBL] [Abstract][Full Text] [Related]
12. Abaloparatide is more potent than teriparatide in restoring bone mass and strength in type 1 diabetic male mice.
Marino S; Ozgurel SU; McAndrews K; Cregor M; Villaseñor A; Mamani-Huanca M; Barbas C; Gortazar A; Sato AY; Bellido T
Bone; 2024 Apr; 181():117042. PubMed ID: 38360197
[TBL] [Abstract][Full Text] [Related]
13. One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption.
Varela A; Chouinard L; Lesage E; Smith SY; Hattersley G
J Bone Miner Res; 2017 Jan; 32(1):24-33. PubMed ID: 27748532
[TBL] [Abstract][Full Text] [Related]
14. Long-Term High-Dose Resveratrol Supplementation Reduces Bone Mass and Fracture Strength in Rats.
Ornstrup MJ; Brüel A; Thomsen JS; Harsløf T; Langdahl BL; Pedersen SB
Calcif Tissue Int; 2018 Mar; 102(3):337-347. PubMed ID: 29058054
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.
Smith BJ; Bu SY; Wang Y; Rendina E; Lim YF; Marlow D; Clarke SL; Cullen DM; Lucas EA
Bone; 2014 Jan; 58():151-9. PubMed ID: 24125756
[TBL] [Abstract][Full Text] [Related]
16. Activin type IIA decoy receptor and intermittent parathyroid hormone in combination overturns the bone loss in disuse-osteopenic mice.
Brent MB; Lodberg A; Bromer FD; van der Eerden BCJ; Eijken M; Brüel A; Thomsen JS
Bone; 2021 Jan; 142():115692. PubMed ID: 33069923
[TBL] [Abstract][Full Text] [Related]
17. Abaloparatide Exerts Bone Anabolic Effects with Less Stimulation of Bone Resorption-Related Factors: A Comparison with Teriparatide.
Makino A; Takagi H; Takahashi Y; Hase N; Sugiyama H; Yamana K; Kobayashi T
Calcif Tissue Int; 2018 Sep; 103(3):289-297. PubMed ID: 29725706
[TBL] [Abstract][Full Text] [Related]
18. Effects of risedronate in a rat model of osteopenia due to orchidectomy and disuse: densitometric, histomorphometric and microtomographic studies.
Libouban H; Blouin S; Moreau MF; Baslé MF; Audran M; Chappard D
Micron; 2008 Oct; 39(7):998-1007. PubMed ID: 18023586
[TBL] [Abstract][Full Text] [Related]
19. Bone anabolic effects of separate and combined therapy with growth hormone and parathyroid hormone on femoral neck in aged ovariectomized osteopenic rats.
Wang L; Orhii PB; Banu J; Kalu DN
Mech Ageing Dev; 2001 Jan; 122(1):89-104. PubMed ID: 11163626
[TBL] [Abstract][Full Text] [Related]
20. Effects of separate and combined therapy with growth hormone and parathyroid hormone on lumbar vertebral bone in aged ovariectomized osteopenic rats.
Wang L; Orhii PB; Banu J; Kalu DN
Bone; 2001 Feb; 28(2):202-7. PubMed ID: 11182379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
